Skip to main content

Table 5 Changes in treatment pattern by patients

From: Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

  Sunitinib
251
Sorafenib
62
Pazopanib
56
Everolimus
70
Temsirolimus
37
Bevacizumab
5
  Pre
143
Post
108
Pre
43
Post
19
Pre
1
Post
55
Pre
34
Post
36
Pre
19
Post
18
Pre
4
Post
1
Number of cycles administered
Median (Q1–Q3) 4.0
(2.0–5.0)
4.0
(2.0–5.0)
3.0
(2.0–5.0)
3.0
(2.0–8.0)
1.0
(1.0–1.0)
3.0
(2.0–5.0)
3.0
(2.0–5.0)
4.0
(2.0–6.0)
2.0
(1.0–4.0)
2.5
(2.0–4.0)
3.5
(2.5–4.5)
10.0
(10.0–10.0)
*Treatment modification, n cycles (%)
Dose reduction 24 (16.8) 16 (14.8) 4 (9.3) 1 (5.3) 0 (0.0) 4 (7.3) 1 (2.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Dose interruption 8 (5.6) 9 (8.3) 2 (4.7) 2 (10.5) 0 (0.0) 4 (7.3) 3 (8.8) 4 (11.1) 1 (5.3) 1 (5.6) 0 (0.0) 0 (0.0)
Treatment discontinuation 6 (4.2) 5 (4.6) 3 (7.0) 0 (0.0) 0 (0.0) 5 (9.1) 0 (0.0) 3 (8.3) 2 (10.5) 2 (11.1) 0 (0.0) 0 (0.0)
Dose increased 0 (0.0) 0 (0.0) 1 (2.3) 2 (10.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
  1. *p between groups >0.05. Length of cycles according to routine clinical practice: sunitinib 6 weeks; other treatments 4 weeks
\